Navneet Ramesh's Archive

Navneet is a sophomore at the University of California – Los Angeles. He is majoring in Molecular, Cell, and Developmental Biology and minoring in Biomedical Research. Navneet would like to attend medical school after completing his undergraduate education. In his spare time, he enjoys playing basketball, catching up on technology-related news, and watching comedy movies. Navneet joined The Myeloma Beacon team in August 2012.

Navneet Ramesh has written 79 article(s) .

[ by and | May 2, 2014 4:53 pm | 2 Comments ]
Researchers Review Current Diagnostic Imaging Techniques For Multiple Myeloma

A group of European researchers recently published an extensive review of the imaging techniques currently used in the diagnosis and follow-up of multiple myeloma and related diseases.

The researchers assessed the benefits and limitations of several dif­fer­ent imaging techniques, including traditional X-rays, computed to­mog­ra­phy (CT), combined positron emission to­mog­ra­phy and CT scan­ning (PET/CT), and magnetic resonance imaging (MRI).

According to the researchers, the whole-body X-ray skeletal survey re­mains the method of choice for the detection of bone lesions. However, they …

Tags: , , , , ,
Read the full story »
[ by and | Apr 8, 2014 7:41 am | 11 Comments ]
Minimal Residual Disease, Deep Sequencing, And Prognosis In Multiple Myeloma

A recent Spanish study adds important findings to the growing literature about the measurement and significance of minimal residual disease in multiple myeloma.

Myeloma patients are said to have minimal residual disease if, after having responded well to treatment, they nevertheless continue to have myeloma cells in their bodies.

In their study, the Spanish researchers used a sensitive new technique known as deep sequencing to conduct minimal residual disease testing. They used the technique to test for residual disease in …

Tags: , , , , , ,
Read the full story »
[ by and | Apr 2, 2014 6:29 pm | 3 Comments ]
Researchers Publish Results Of Revlimid-Velcade-Dexamethasone Trial In Relapsed Multiple Myeloma

Findings from a prospective Phase 2 clinical trial indicate that the com­bi­na­tion of Revlimid, Velcade, and dexamethasone is effective in relapsed and refractory multiple myeloma patients.

The trial enrolled 64 patients, who had been treated with a median of two prior therapies, at six different U.S. cancer centers from 2006 to 2008.

Nearly two-thirds of the patients in the trial achieved at least a partial re­sponse, despite the fact that more than half of the patients had previous­ly been treated …

Tags: , , , , , , , , ,
Read the full story »
[ by and | Mar 17, 2014 4:47 pm | 4 Comments ]
Regular Whole-Body MRI Scans May Identify Smoldering Myeloma Patients At High Risk For Progression

Results from a German retrospective study show that repeated whole-body mag­netic resonance imaging may identify smoldering myeloma patients with an increased risk of progressing to symptomatic multiple myeloma.

In their study, the German researchers looked at smoldering myeloma patients who had whole-body magnetic resonance imaging (MRI) scans at the time of diagnosis and during regular follow-up visits.

The researchers found that patients whose follow-up scans showed pro­gres­sion of their disease had a 16.5-fold higher risk of progressing to symptomatic myeloma …

Tags: , , , ,
Read the full story »
[ by and | Mar 13, 2014 6:34 am | 4 Comments ]
Patterns Of Post-Transplant Relapse And Progression Vary Among Multiple Myeloma Patients

A group of Spanish researchers published a summary last year of the patterns of re­lapse and progression they observed in multiple myeloma patients who underwent stem cell trans­plan­ta­tion as part of their upfront therapy.

The researchers observed re­lapse in over half of the patients included in the study.  Among these patients, the majority had only achieved a partial re­sponse after trans­plan­ta­tion.

They also found that how a patient re­lapsed had an impact on their prog­nosis after re­lapse.  Patients who re­lapsed …

Tags: , , , ,
Read the full story »